Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Inflammatory Bowel Diseases

• Publication date

  2018-01-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ibd/izx018PMID 29361090
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

  2015cited by this paper
• Converging goals of treatment of inflammatory bowel disease from clinical trials and practice.

  2015cited by this paper
• A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

  2015cited by this paper
• Health determining concepts important to people with Crohn's disease and their coverage by patient-reported outcomes of health and wellbeing

  2014cited by this paper
• Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease.

  2014cited by this paper
• The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome

  2013cited by this paper
• NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people

  2013cited by this paper
• Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease

  2012cited by this paper
• Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

  2012cited by this paper
• Evaluation of a daily practice composite score for the assessment of Crohn’s disease: the treatment impact of certolizumab pegol

  2011cited by this paper
• Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

  2011cited by this paper
• Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI

  2010cited by this paper
• How Rapidly Should Remission Be Achieved?

  2010cited by this paper
• Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.

  2010cited by this paper
• Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment

  2010cited by this paper
• Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings

  2008cited by this paper
• Defining the Optimal Response Criteria for the Crohn's Disease Activity Index for Induction Studies in Patients With Mildly to Moderately Active Crohn's Disease

  2008cited by this paper
• Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices

  2008cited by this paper
• Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.

  2008cited by this paper
• Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level

  2007cited by this paper
• Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease

  2007cited by this paper
• Validation of the mainland Chinese version of the inflammatory bowel disease questionnaire (IBDQ) for ulcerative colitis and Crohn's disease

  2007cited by this paper
• Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

  2006cited by this paper
• Qualitative research for allied health professionals: challenging choices

  2006cited by this paper
• Laboratory markers in IBD: useful, magic, or unnecessary toys?

  2006cited by this paper
• Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease

  2006cited by this paper
• Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease

  2005cited by this paper
• Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.

  2004cited by this paper
• Comparison between Prospective and Retrospective Evaluation of Crohn's Disease Activity Index

  2003cited by this paper
• A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.

  2002cited by this paper
• Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

  2001cited by this paper
• Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system.

  1997cited by this paper
• Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease.

  1997cited by this paper
• Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

  1994cited by this paper
• Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

  1990cited by this paper
• Classification of inflammatory bowel disease.

  1989cited by this paper
• Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

  1989cited by this paper
• A new measure of health status for clinical trials in inflammatory bowel disease.

  1989cited by this paper
• IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease.

  1987cited by this paper
• Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease.

  1986cited by this paper
• Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

  1976cited by this paper

• Fecal leukocyte esterase levels predict endoscopic severity as an alternative biomarker in inflammatory bowel disease

  2025cites this paper
• Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis on the use of Telemedicine in Inflammatory Bowel Disease

  2025cites this paper
• Patient-reported outcome measures poorly correlate with objective inflammatory bowel disease activity measures: a systematic review

  2025cites this paper
• Neue Therapie-Targets bei chronisch-entzündlichen Darmerkrankungen?

  2024cites this paper
• Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of Telemedicine in Inflammatory Bowel Disease.

  2024cites this paper
• Differentiating clinical characteristics of perianal inflammatory bowel disease from perianal hidradenitis suppurativa

  2024cites this paper
• To STRIDE or not to STRIDE: a critique of “treat to target” in Crohn´s disease

  2023influential citation
• Disease Flares Following COVID-19 Vaccination in Patients with Inflammatory Bowel Disease

  2023cites this paper
• Combined use of CDAI and blood indices for assessing endoscopic activity in ileocolic Crohn’s disease

  2023cites this paper
• Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn’s Disease

  2022cites this paper
• Modification of blood-based (IgG) to salivary-based (IgA) ELISA for Inflammatory Bowel Disease Diagnostic: Tumor necrosis factor (TNF) alpha quantification

  2022cites this paper
• Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity

  2021cites this paper
• Utilizing Patient-Reported Outcome Measures in the Management of Inflammatory Bowel Disease

  2020cites this paper
• Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study

  2020cites this paper
• Correlation of Patient-Reported Outcome (PRO-2) with Endoscopic and Histological Features in Ulcerative Colitis and Crohn's Disease Patients

  2020cites this paper
• The New Proactive Approach and Precision Medicine in Crohn’s Disease

  2020cites this paper
• STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.

  2020cites this paper
• Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease?

  2019cites this paper
• Systematic review and external validation of prediction models based on symptoms and biomarkers for identifying endoscopic activity in Crohn's disease.

  2019cites this paper
• Assessment of Machine Learning Detection of Environmental Enteropathy and Celiac Disease in Children

  2019cites this paper
• Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations

  2019cites this paper
• World Journal of Gastroenterology

  year unknowncites this paper